Biotechnology Recognized for contribution to renewable energy. – ThomasNet Industrial News Room (press release)
By Dr. Matthew Watson
Biotechnology Recognized for contribution to renewable energy. ThomasNet Industrial News Room (press release) June 28, 2013 - BIO applauded President Barack Obama's recognition of contributions made by biotechnology to design of new biofuels and to agricultural productivity in the President's Climate Action Plan. BIO President and CEO Jim Greenwood ... BIO Applauds Legislation That Levels the Playing Field for Renewable ChemicalsThe Herald | HeraldOnline.com |
A joint campaign against GM crops, Biotechnology Bill – The Hindu
By Dr. Matthew Watson
The Hindu | A joint campaign against GM crops, Biotechnology Bill The Hindu Cutting across party lines, several political leaders participated on Tuesday in a joint campaign with civil society groups and farmers' organisations against Genetically Modified crops and the Biotechnology Regulatory Authority of India (BRAI) Bill at ... |
Prosensa Holding (RNA) IPO Opens Sharply Higher – StreetInsider.com (subscription)
By Dr. Matthew Watson
Prosensa Holding (RNA) IPO Opens Sharply Higher StreetInsider.com (subscription) Prosensa Holding is an innovative biotechnology company engaged in the discovery and development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company's primary focus is on rare ... Prosensa leaps in 1st day of Nasdaq tradingThe Idaho Statesman |
Puma Biotechnology to Join Russell 3000 Index – EON: Enhanced Online News (press release)
By Dr. Matthew Watson
Puma Biotechnology to Join Russell 3000 Index EON: Enhanced Online News (press release) LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, is set to join the broad-market Russell 3000® Index following Russell Investments' annual reconstitution of its comprehensive set ... |
OICR congratulates Dr. Thomas J. Hudson on being named to the Order of … – Canada NewsWire (press release)
By Dr. Matthew Watson
OICR congratulates Dr. Thomas J. Hudson on being named to the Order of ... Canada NewsWire (press release) In 2007, Dr. Hudson was appointed Professor in the Departments of Molecular Genetics and Medical Biophysics at the University of Toronto and he is a fellow of the Royal Society of Canada. He is editor-in-chief of the journal Human Genetics and has ... |
Targeted viral therapy destroys breast cancer stem cells in preclinical … – EurekAlert (press release)
By Dr. Matthew Watson
Targeted viral therapy destroys breast cancer stem cells in preclinical ... EurekAlert (press release) ... Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics program at VCU Massey, chairman of VCU School of Medicine's Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine. |
Angelina Jolie, Medical College of Wisconsin and genome sequencing – The Business Journal of Milwaukee (blog)
By Dr. Matthew Watson
Angelina Jolie, Medical College of Wisconsin and genome sequencing The Business Journal of Milwaukee (blog) Howard Jacob, director of the college's Human and Molecular Genetics Center, told me. “That's really where we want to spend our time. There are plenty of places out there that have more firepower in the research arena than we do.” Rich Kirchen is The ... |
Ami Ahern-Rindell Brings 20 Years of Experience to Undergraduate Research … – Newswise (press release)
By Dr. Matthew Watson
Ami Ahern-Rindell Brings 20 Years of Experience to Undergraduate Research ... Newswise (press release) She earned her M.S. and Ph.D. degrees in Genetics and Cell Biology from Washington State University and was an NIH Postdoctoral Fellow at the Center for Molecular Genetics at the University of California, San Diego. In 1992, she received her first ... |
RUSNANOPRIZE Award 2013 for Achievements in Nanomaterials and Surface … – AZoNano.com
By Dr. Matthew Watson
AZoNano.com | RUSNANOPRIZE Award 2013 for Achievements in Nanomaterials and Surface ... AZoNano.com Professor Lukyanov also had a successful business in the field of molecular genetics, and a score of 40 in the Hirsch Index at the same time. Anatoly Chubays, the RUSNANO CEO, presents the RUSNANOPRIZE Award to Prof. Sergey Lukyanov at the 2012 ... |
Student news published June 28, 2013 – Helena Independent Record
By Dr. Matthew Watson
Student news published June 28, 2013 Helena Independent Record A 2010 graduate in cell biology, Harlen will use his fellowship to research molecular genetics in the department of genetics at Harvard Medical School. He would eventually like to become a professor. MedStart Summer Camp attendees. Kaitlin Kroll and ... |
Cost of a Stem Cell Therapy? An Estimated $512,000
By Dr. Matthew Watson
and cures receive almost no attention in the media as well as
publicly from scientists and the biotech firms.
obliquely framed in the context of “reimbursement,” as if
industry is owed something instead of making a business decision
about what will make a profit. Euphemisms and jargon cloak unpleasant realities such as astronomical patient costs. But what reimbursement really involves are, in fact, pricing decisions and profit margins along with
lobbying campaigns for inclusion of
therapies in normal coverage of health insurance and Medicare.
for one stem cell treatment – appeared in the Wall Street
Journal . The story by Kosaku Narioka and Phred Dvorak dealt
with what would be the first-ever human study of a treatment that
uses reprogrammed adult stem cells.
preliminary approval on Wednesday from a key panel of the Japan
Health Ministry. The treatment involves a form of age-related macular
degeneration, which has also been targeted by the California stem
cell agency with different approaches.
article, with little other discussion, was this sentence:
“One eventual obstacle, even if tests
go well, could be cost: (Masayuki) Yamato (of Tokyo Women's Medical
University) says initial estimates for the treatment run around ¥50
million ($512,000) per person."
cell treatments has rattled around in the background for years
without much deep public discussion. One reason is that high costs of
treatments are controversial and can trigger emotional debate.
Another reason is that it is very early in the therapy development
process and estimates are not likely to be entirely reliable.
cell agency commissioned a study involving costs of stem cell therapies. The UC Berkeley report said,
“The cost impact of the therapy is
likely to be high, because of a therapy’s high cost per patient,
and the potentially large number of individuals who might benefit
from the therapy. This expense would put additional stress on
the Medicare and Medicaid budgets, cause private
insurance health premiums to increase, and create an incentive for
private plans to avoid covering individuals eligible for a therapy.”
welcomed. The agency sat on the 2009 study for seven months until it
was uncovered by the California Stem Cell Report in April 2010. Then
the agency was careful to say that the study did not reflect the view
of CIRM management or board leadership.
to both patient accessibility and therapy development. If companies
cannot make a profit on a possible therapy, it is virtually certain
not to appear in the marketplace.
background, it does not mean there is a lack of interest. The copy of
the Berkeley stem cell cost study that was posted online by the California
Stem Cell Report has been read 11,701 times since it was made
available in April 2010 on scribd.com.
Bluebird and Banking: Media Pluses for California Stem Cell Agency
By Dr. Matthew Watson
a couple of favorable publicity points last week as the result of a
successful stock offering by an award recipient and another piece
about creation of a stem cell bank in Northern California.
preferred spelling) of Massachusetts was a big winner for the
company, raising millions of dollars more than anticipated.
“Shares of the Cambridge life
sciences company bluebird bio Inc. soared almost 60 percent on their
first day of trading (last) Wednesday, an impressive debut for a
business that endured years of stagnation and another encouraging
sign for the biotechnology industry.
“The local gene therapy company
raised $101 million in an initial public offering priced at $17 per
share, higher than the $14 to $16 estimated by investment bankers.
Bluebird shares closed at $26.91 per share on Wednesday.”
a share at the time of this writing, which is good news generally for
the biotech industry.
award last fall from the $3 billion stem cell agency. The company has yet to receive any actual cash from the agency as both parties work
out final details of an agreement, a spokesman for the agency said
last week.
successful IPO in a blog item by that said,
“Bluebird Bio, one of the oldest
companies in the struggling gene therapy field, is having an
outstanding first day in the stock market today, and largely by
marrying its gene therapy technology with stem cell science. The
company’s financial milestone brings hope and excitement to both
fields.”
failed to mention the stem cell agency's involvement, which would
have been nice for the agency but was to be expected given the way
news is covered.
appeared on Xconomy, an Internet news service dealing with
technology. Written by Bernadette Tansey, a former San Francisco
Chronicle reporter, the piece dealt with the both business and science of stem cell banking. She wrote,
“One of the main goals of
California’s $3 billion stem cell research agency is to draw
companies into the state so they can vie for a share of the funding.
"With a recently funded $32 million
initiative, the California
Institute for Regenerative Medicine(CIRM) has attracted two of
the biggest US players in stem cell banking to Novato, CA, to form
one of the largest biobanks of induced pluripotent stem cells (iPS
cells) in the world.”
minor staple in recent news coverage of CIRM, surfacing in a number
of articles since the awards were approved. One of the reasons for that is that the project has a relatively straight-forward story line compared to many research efforts and the concept of "banking" is familiar to editors, writers and readers.
Stem Cell Therapy Becomes More Widely Available | Video ABC News – Video
By daniellenierenberg
Stem Cell Therapy Becomes More Widely Available | Video ABC News
Beverly Hills Orthopedic surgeon Dr. Raj appeared on ABC #39;s Good Morning America to share the breatkthrough stem cell treatment that #39;s now available to weeken...
By: AHPRvideo
Continued here:
Stem Cell Therapy Becomes More Widely Available | Video ABC News - Video
Punto por Punto: Phil Medical Association, nagbabala sa iligal na pagsasagawa ng stem cell therapy – Video
By JoanneRUSSELL25
Punto por Punto: Phil Medical Association, nagbabala sa iligal na pagsasagawa ng stem cell therapy
MANILA - Punto por Punto host Anthony Taberna discusses the possible dangers of illegal stem cell therapy.
By: TheABSCBNNews
63 year old stroke victim was greatly improved through stem cell therapy – Video
By daniellenierenberg
63 year old stroke victim was greatly improved through stem cell therapy
By: Gökhan Akdo #287;an
Read the original:
63 year old stroke victim was greatly improved through stem cell therapy - Video
Cell Therapy Catapult – World Stem Cells Regenerative Medicine Congress 2013 – Video
By raymumme
Cell Therapy Catapult - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...
By: biopharmachannel
See more here:
Cell Therapy Catapult - World Stem Cells Regenerative Medicine Congress 2013 - Video
Foreign doctors behind illegal stem cell therapy – Video
By LizaAVILA
Foreign doctors behind illegal stem cell therapy
The Philippine Medical Association wants to go after foreign doctors who are reportedly conducting unauthorized stem cell procedures in the country.
By: TheABSCBNNews
Visit link:
Foreign doctors behind illegal stem cell therapy - Video
Paralyzed German Shepard Receives Revolutionary Stem Cell Therapy! – Video
By JoanneRUSSELL25
Paralyzed German Shepard Receives Revolutionary Stem Cell Therapy!
By: Stemlogix, LLC
See more here:
Paralyzed German Shepard Receives Revolutionary Stem Cell Therapy! - Video
DOH: Solons who died after stem cell therapy were sick
By LizaAVILA
MANILA - Two congressmen who died after undergoing stem cell therapy abroad were already sick before getting treatment, Health Secretary Enrique Ona said Tuesday.
Speaking to reporters, Ona refused to say if stem cell treatment caused the deaths of congressmen Erico Aumentado and Pedro Romualdo. Both lawmakers died of pneumonia.
"First hindi ko alam yun. Second, ang information that we got: It has nothing to do Ibig sabihin, they were already very sick bago nagpa-so-called stem call, baka sakali," he said in the interview.
On the other hand, the health secretary said clinics or hospitals in the Philippines offering stem cell treatments should be duly licensed by the Department of Health.
Dapat yung mga clinic or mga ospital na gumagawa noon kailangang mayroong license, approved ngayon ng DOH. Kaya iinspekyunin sila," he said.
House Speaker Sonny Belmonte earlier confirmed Aumentado and Romualdo had died after undergoing stem cell treatment in Germany last year. He clarified that it has not been established whether stem cell therapy was the cause of death.
Belmonte said that after having stem cell therapy, the 2 felt rejuvenated and may have exerted themselves during the last election campaign.
Belmonte said Aumentado even started walking around without a cane.
Aumentado's son, Aristotle, earlier said his father had leg thrombosis for which he had to undergo bifemoral bypass and stem cell therapy .
After stem cell therapy, his father started walking without a cane, and sometimes had low-blood sugar. However, he said they forgot to get him stem cell treatment for his father's pneumonia, which he had before the stem cell treatment in Germany last September.
Here is the original post:
DOH: Solons who died after stem cell therapy were sick
House seeks probe on stem-cell therapy link to solons’ deaths
By Sykes24Tracey
Should there be a law on stem cell therapy? The House of Representatives (HOR) has no idea. And for the sake of finding answer, House leaders intend to consult with medical experts about the issues surrounding the procedure. Speaker Feliciano Sonny Belmonte Jr. admits lawmakers need an expert opinion before they take any legislative action on reports about the negative effects of the expensive treatment. At this point, we have absolutely no basis to say that it was wrong (or) it wasnt wrong (or) it should be regulated, it should not be regulated, Belmonte said. Belmonte issued the statement after the Philippine Medical Association (PMA) said it is looking into the recent deaths of three politicians, who died after receiving xenogenic treatment in Germany. PMA president Dr. Leo Olarte said his group is still trying to find out whether politicians died due to their illness or due to hypersensitive reaction from animal-based stem cell treatments they received. On Monday, Belmonte revealed that Camiguin Rep. Pedro Romualdo underwent stem cell treatment in Germany before he died in April due to pneumonia. Incoming Bohol Rep. Aris Aumentado also admitted his father, the late Bohol Rep. Erico Aumentado, had undergone similar treatment in September before he died last Christmas, also due to pneumonia. We are still awaiting the word of the experts and the medical experts, not political experts on how, if anything, is demanded from us, Belmonte said. Olarte, who is the spokesperson of Philippine Society for Stem Cell Medicine, cited initial information that the politicians received stem cell therapy that used sheeps. He reiterated that receiving animal-based stem cell is dangerous because it may trigger complications such as graft versus host reaction. The expert advised Filipinos and public officials to choose autologous adult stem cell treatment, which is derived from the patients own blood, bone marrow or fat. Last March, the Department of Health (DOH) has restricted hospitals and other facilities from using genetically-altered cells and tissues of human in carrying out stem-cell therapy and treatments in the country. Health secretary Enrique Ona added their department also prohibits the use of umbilical cord, fat-derived human stem cells, and live animal stem cells for the conduct of the procedure locally.
ONA released Administrative Order (AO) 2013-0012, which seeks to ensure the safety of people who want to undergo human stem cell and cell-based therapies.
Excerpt from:
House seeks probe on stem-cell therapy link to solons' deaths